In a follow-up study, the same group further reported increased apoptosis after ex vivo treatment of human prostate cancers by a combinatorial treatment including the MTAP inhibitor Methylthio-DADMe-Immucillin-A (MTDIA). The gene discussed is MTAP; the disease is prostate carcinoma.